1. Introduction {#s1}
===============

Anemia is a common clinical condition in patients with acute coronary syndromes (ACS), especially in elderly patients with comorbidities.[@b1] The progressive ageing of population is leading to an increase in the number of patients with ACS and anemia.[@b2] Importantly, patients with anemia are usually excluded from clinical trials, and information regarding their optimal management is scarce.[@b3] Patients with anemia are commonly managed conservatively in routine clinical practice.[@b4],[@b5] In a not negligible proportion of cases, these patients are denied intensive therapies because of perception of short life expectancy and fear of complications. Little information exists about anemia in ACS patients admitted to intensive care units.[@b6],[@b7] The aim of this study was to assess the prevalence of anemia and its impact on management and outcomes in consecutive patients with non ST segment elevation ACS (NSTEACS) admitted to Intensive Cardiac care Units (ICCU).

2. Methods {#s2}
==========

2.1. Design and study population {#s2a}
--------------------------------

This is a multicenter registry carried out in eight hospitals of Catalonia during a period of 6 months (between October 1, 2017 to March 31, 2018). This study was endorsed and coordinated by the Working Group on Acute Cardiac Care of the Catalan Society of Cardiology.

All consecutive patients admitted to the ICCUs of the participating centers with a diagnosis of NSTEACS were prospectively included. NSTEACS was defined as the presence of chest pain compatible with acute coronary syndrome with at least one of the following: (1) electrocardiographic abnormalities suggesting myocardial ischemia and (2) elevation of troponin. The only exclusion criteria was the impossibility of obtaining informed consent for participation in the registry.

2.2. Data collection {#s2b}
--------------------

Data were prospectively collected during admission by local researchers, using specific standardized case report forms. Demographic data, baseline clinical characteristics, analytical, electrocardiographic and echocardiographic data were recorded, as well as the performance of coronary angiography. Information about in-hospital clinical course (treatments administered, requirement of invasive procedures, complications and in-hospital mortality) was also collected. The CRUSADE[@b8] and GRACE[@b9] risk scores were calculated for each patient. The hemodynamic parameters (heart rate, systolic blood pressure) and Killip class were recorded upon admission to the ICCU. Creatinin clearance was calculated by the Cockcroft-Gault formula.[@b10] Body surface area was calculated using the Mosteller formula.[@b11] Anemia at admission was defined by the World Health Organisation criteria (hemoglobin \< 130 g/L in men and \< 120 g/L in women).[@b12]

Patients\' risk profile was defined by the criteria of the European Society of Cardiology.[@b13] Patients with very high risk were considered those who presented at least one of the following conditions: refractory angina, hemodynamic instability, cardiogenic shock, acute heart failure, ventricular arrhythmias or cardiorespiratory arrest. Likewise, high-risk patients were considered those with elevated serum troponin, diabetes mellitus or GRACE scale values \> 140, without very high risk criteria.

Management of patients was done according to current recommendations. Antithrombotic treatment and coronary angiography were left to the discretion of the medical team. If coronary angiography was performed, vascular access, antithrombotic drugs and the choice of stents and other devices were lead to operator\'s decision.

Clinical follow-up was carried out at six months by medical visit, review of medical records or telephone contact with the patient, family or referring physician. The main outcome measured of the study was mortality or readmission at six months of follow-up. The assignment of the cause of death was based on clinical judgment of the physician taking care of the patient at the time of death. Death was deemed cardiac when it was be due to myocardial infarction, heart failure or sudden death. The incidence of reinfarction and new coronary revascularizations were also recorded.

2.3. Statistical analysis {#s2c}
-------------------------

The analysis of normal distribution of variables was performed using the Shapiro-Wilk test. Quantitative variables are expressed as mean ± SD. Non-normally distributed variables are expressed as median and interquartile range. Categorical variables are expressed as number and percentage.

Baseline characteristics, clinical management and in-hospital clinical course were compared across if anemia was present. The association between categorical variables was analyzed with the Chi-square test, with the correction of continuity when indicated. The analysis of quantitative variables according to anemia status was performed by Student\'s *t* test. The association between anemia and mortality or readmission at 6 months was assessed by the Cox regression method. Variables included in the multivariate analysis[@b14] were those with an association (*P* \< 0.2) both with exposition (anemia) and effect (mortality or readmission at 6 months, see table), and not considered to be an intermediate variable between them.

Survival analysis was performed using Kaplan Meier curves. Statistical significance of differences was assessed by log rank test. The PASW Statistics 18 (Chicago, IL, USA) was used for all analysis.

3. Results {#s3}
==========

A total of 629 patients were included across the study period, of whom 483 (76.7%) were male. Mean age was 66.6 years.

Globally, patients from this series had a high risk profile, with a significant proportion of comorbidities such as diabetes mellitus (238/629, 37.8%), peripheral artery disease (106/629, 16.9%) or previous stroke (56/629, 8.9%). Most patients had elevated serum troponin levels (574/629, 91.3%), and almost one of each five patients had signs of heart failure at admission (119/629, 18.9%). Coronary angiography during the admission was performed in the vast majority of patients (605/629, 96.2%). A total of 197 patients (31.3%) had anemia at admission.

3.1. Clinical characteristics according to anemia status {#s3a}
--------------------------------------------------------

Patients with anemia were significantly older, with a higher prevalence of cardiovascular risk factors and comorbidities such as peripheral artery disease, previous stroke or previous malignancy. They also had a higher prevalence of previous myocardial infarction and higher degree of comorbidity as measured by the Charlson index ([Table 1](#jgc-17-01-035-t01){ref-type="table"}). Patients with anemia had also poorer renal function and higher glucose levels at admission and lower levels of LDL cholesterol. These patients had higher risk criteria than the rest of patients, with a higher incidence of heart failure at admission, poorer left ventricle ejection fraction and higher GRACE, CRUSADE and PRECISE-DAPT scores values.

###### Clinical characteristics according to anemia status.

                                                 Anemia (*n* = 197)   No anemia (*n* = 432)   *P*-value
  --------------------------------------------- -------------------- ----------------------- -----------
  Age, yrs                                           71.6 ± 11              64.3 ± 12           0.001
  Male sex                                          154 (78.2%)            329 (76.2%)          0.579
  BMI, kg/m^2^                                       27.3 (7%)              27.9 (5%)           0.201
  BSA, m^2^                                         1.85 (0.2%)            1.91 (0.2%)          0.001
  Active smoking                                     31 (15.8%)            151 (35.3%)          0.001
  Diabetes mellitus                                 110 (55.8%)            128 (29.6%)          0.001
  Hypertension                                      173 (88.3%)            289 (66.9%)          0.001
  Dyslipidemia                                       161 (83%)             373 (63.3%)          0.001
  Previous myocardial infarction                     74 (37.8%)            89 (20.7%)           0.001
  Previous percutaneous coronary intervention        63 (32.1%)            78 (18.1%)           0.001
  Previous treatment with ASA                       122 (61.9%)            124 (28.7%)          0.001
  Previous treatment with P2Y12 inhibitors           49 (24.9%)            57 (13.2%)           0.001
  Previous treatment with OAC                        22 (11.1%)            45 (10.4%)           0.745
  Previous heart failure                             22 (11.2%)             33 (7.7%)           0.143
  Previous atrial fibrillation                       23 (11.7%)             43 (10%)            0.501
  Previous stroke                                    27 (13.7%)             29 (6.7%)           0.009
  Peripheral artery disease                          52 (26.4%)            54 (12.5%)           0.001
  Previous malignancy                                35 (17.9%)            45 (10.4%)           0.010
  Previous bleeding                                  16 (8.2%)               13 (3%)            0.004
  Charlson comorbidity index                          3.2 ± 2%               2.2 ± 2            0.001
  **Clinical characteristics**                                                               
   Creatinine clearance, mL/min                       60 (35%)              99 (41%)            0.001
   Haemoglobin at admission, g/dL                   10.9 (1.4%)            14.5 (1.2%)          0.001
   Glucose at admission, mg/dL                       165 (84%)              146 (77%)           0.008
   LDL cholesterol, mg/dL                             77 (29%)              106 (72%)           0.001
   Killip class at admission \> I                     65 (33%)             54 (12.5%)           0.001
   Systolic blood pressure, mmHg                     138 (25%)              137 (26%)           0.712
   Heart rate, beats/min                              80 (20%)              78 (17%)            0.065
   Positive troponin                                180 (91.4%)            394 (91.2%)          0.945
   *GRACE* score                                      156 ± 34              133 ± 34            0.001
   *CRUSADE* score                                    43 ± 17                22 ± 14            0.001
   *PRECISE-DAPT* score                               35 ± 15                17 ± 12            0.001
   High-risk criteria                               102 (51.8%)            290 (67.6%)          0.001
   Very high risk criteria                           93 (47.2%)            132 (30.8%)          0.001

Data are presented as mean ± SD or *n* (%). ASA: acetilsalicyilic acid; BMI: body mass index; BSA: body surface area; LDL: low density lipoprotein; OAC: oral anticoagulant drugs.

3.2. In hospital clinical management and outcomes according to anemia status {#s3b}
----------------------------------------------------------------------------

Patients with anemia underwent less often coronary angiography during the admission, with a higher proportion of multivessel disease and left main coronary stenosis, but without significant differences regarding coronary revascularization ([Table 2](#jgc-17-01-035-t02){ref-type="table"}).

###### In-hospital management according to anemia status.

                                          Anemia (*n* = 197)   No anemia (*n* = 432)   *P*-value
  -------------------------------------- -------------------- ----------------------- -----------
  **In-hospital medical treatment**                                                   
   ASA                                        195 (99%)              431 (99%)           0.183
   Clopidogrel                               158 (80.6%)             257 (60%)           0.001
   Ticagrelor                                 42 (21.3%)            187 (43.4%)          0.001
   Prasugrel                                   6 (3.1%)              24 (5.6%)           0.226
   Enoxaparin                                101 (51.8%)            246 (57.6%)          0.175
   Fondaparinux                               44 (22.7%)            117 (27.3%)          0.225
   Unfractionated heparin                     54 (27.7%)            108 (25.2%)          0.506
   Abciximab                                    2 (1%)               2 (0.5%)            0.373
   Inotropes                                  19 (9.6%)              28 (6.5%)           0.169
   Amiodarone                                 19 (9.6%)              21 (4.9%)           0.023
   Diuretics                                 106 (54.1%)            110 (25.6%)          0.001
   Betablockers                              154 (78.2%)            344 (80.8%)          0.455
   Ivabradin                                  16 (8.1%)              15 (3.5%)           0.013
   Ranolazine                                  5 (2.5%)              4 (0.9%)            0.149
   ACEI                                      114 (58.2%)            301 (70.3%)          0.003
   Eplerenone                                 18 (9.1%)              26 (6.1%)           0.167
   Statins                                    193 (98%)             420 (97.4%)          0.786
   Ezetimibe                                  10 (5.1%)              23 (5.4%)           0.882
   Insulin                                   113 (57.4%)            136 (31.6%)          0.001
   Oral antidiabetic drugs                     8 (4.1%)               17 (4%)            0.948
   Proton pump inhibitors                    196 (99.5%)            416 (97.2%)          0.117
  **In-hospital procedures**                                                          
   Angiography                               181 (91.9%)            424 (98.1%)          0.001
   Time to angiography, h                    21.8 (4--61)          19.6 (3--44)          0.123
   Multivessel disease                       109 (60.2%)             191 (45%)           0.009
   Left main disease                          39 (21.5%)            57 (13.4%)           0.015
  **Revascularization**                                                               
   None                                       72 (36.5%)            134 (31.0%)       
   Percutaneous                              108 (54.8%)            254 (58.8%)       
   Surgical                                   19 (9.6%)             44 (10.2%)           0.488
   Temporary pacemaker                         7 (3.6%)              8 (1.9%)            0.193
   Intraaortic counterpulsation               12 (6.1%)              9 (2.1%)            0.015
   Invasive mechanical ventilation            24 (12.2%)            44 (10.2%)           0.453
   Non-invasive mechanical ventilation        26 (13.2%)             20 (4.6%)           0.001
   Therapeutic hypothermia                        0                  4 (0.9%)            0.417
   Renal replacement therapies                13 (6.6%)              3 (0.7%)            0.001
   High flow nasal cannula                    12 (6.1%)              9 (2.1%)            0.015

Data are presented as *n* (%) or median (interquartile range). ASA: acetil salycilic acid; ACEI: angiotensin converter enzyme inhibitors.

Significant differences were also observed regarding in-hospital medical treatment, with a higher proportion of treatment with clopidogrel, amiodarone, diuretics and ivabradine and a lower proportion of treatment with ticagrelor and ACE inhibitors in patients with anemia. In addition, these patients underwent more often invasive in-hospital procedures such as intraaortic counterpulsation, non-invasive mechanical ventilation and renal replacement therapies as compared to patients without anemia.

Patients with anemia had a higher incidence of in-hospital complications such as refractory ischemia, atrioventricular block or atrial fibrillation, without differences in the rate of major bleeding or in-hospital mortality. Both ICU and in-hospital stay were significantly longer in patients with anemia ([Table 3](#jgc-17-01-035-t03){ref-type="table"}).

###### In-hospital clinical outcomes according to anemia status.

                              Anemia (*n* = 197)   No anemia (*n* = 432)   *P*-value
  -------------------------- -------------------- ----------------------- -----------
  Refractory ischemia             20 (10.2%)             16 (3.7%)           0.002
  Reinfarction                     6 (3.1%)              5 (1.2%)            0.107
  Atrioventricular block           9 (4.6%)              5 (1.2%)            0.015
  Ventricular fibrillation         3 (1.5%)              6 (1.4%)            0.895
  Atrial fibrillation             28 (14.4%)             31(7.2%)            0.005
  Stroke                              0                  3 (0.7%)            0.584
  *CRUSADE* major bleeding        17 (8.6%)             44 (10.2%)           0.541
  Need for transfusion            14 (77.8%)             11 (44%)            0.027
  In-hospital mortality            3 (1.5%)              9 (2.1%)            0.634
  ICCU stay                        3 (2--5)              3 (2--4)            0.013
  Hospital stay                   9 (5--15)              6 (4--10)           0.001

Data are presented as *n* (%) or median (interquartile range). ICCU: Intensive cardiac Care Unit.

3.3. Post-discharge management and clinical outcomes according to anemia status {#s3c}
-------------------------------------------------------------------------------

Patients with anemia were more commonly treated with clopidogrel, diuretics, ivabradine, ranolazine and proton pump inhibitors at hospital discharge ([Table 4](#jgc-17-01-035-t04){ref-type="table"}). In contrast, the rate of prescription of ticagrelor and prasugrel was significantly lower in these patients.

###### Management at discharge according to anemia status.

                             Anemia (*n* = 194)   No anemia (*n* = 423)   *P*-value
  ------------------------- -------------------- ----------------------- -----------
  ASA                           181 (93.3%)            394 (93.1%)          0.944
  Clopidogrel                   114 (58.8%)            149 (35.2%)          0.001
  Ticagrelor                     28 (14.4%)            151 (35.7%)          0.001
  Prasugrel                       3 (1.5%)              24 (5.7%)           0.020
  Direct anticoagulants           8 (4.1%)              13 (3.1%)           0.497
  Vitamin K antagonists          18 (9.3%)              51 (12%)            0.314
  Amiodarone                     10 (5.2%)              20 (4.7%)           0.819
  Diuretics                      93 (47.9%)            101 (23.9%)          0.001
  Betablockers                  146 (75.3%)            317 (75.1%)          0.970
  Ivabradin                      22 (11.3%)             12 (2.8%)           0.001
  Ranolazine                      9 (4.6%)              6 (1.4%)            0.034
  ACEI                           98 (50.5%)            245 (57.9%)          0.086
  Eplerenone                     21 (10.8%)             27 (6.4%)           0.056
  Statins                       186 (95.9%)            391 (92.4%)          0.107
  Ezetimibe                      17 (8.8%)              36 (8.6%)           0.937
  Insulin                        61 (31.4%)            54 (12.8%)           0.001
  Oral antidiabetic drugs        68 (35.2%)            99 (23.6%)           0.003
  Proton pump inhibitors        173 (89.2%)            346 (81.8%)          0.020

Data are presented as *n* (%). ASA: acetil salycilic acid; ACEI: angiotensin converter enzyme inhibitors.

From 617 patients surviving at hospital discharge, data on clinical follow up was available in 586 cases (95%). Of them, 33 patients (5.6%) presented new ACS and 17 (2.9%) clinically significant bleeding at 6 months.

Globally, a total of 23 patients died at 6 months and 140 patients dead or were readmitted at 6 months. Both the incidence of mortality (HR = 3.36, 95% CI: 1.43--7.85, *P* = 0.001) and the incidence of mortality or readmission were significantly higher in patients with anemia (HR = 2.80, 95% CI: 2.03--3.86, *P* = 0.001). After adjusting for potential confounders, the association between anemia and mortality or readmission at 6 months was still significant (HR = 2.22, 95% CI: 1.32--3.71, *P* = 0.031, [Table 5](#jgc-17-01-035-t05){ref-type="table"}). [Figure 1](#jgc-17-01-035-g001){ref-type="fig"} shows the cumulative incidence of mortality and mortality or readmission at 6 months according to anemia status.

###### Predictors of mortality or readmission at 6 months.

  Variable                            Univariate analysis   Multivariate analysis                      
  ---------------------------------- --------------------- ----------------------- ------------------- -------
  Anemia                               2.80 (2.03--3.86)            0.001           2.22 (1.32--3.71)   0.031
  Age                                  1.03 (1.02--1.05)            0.001           1.02 (1.00--1.04)   0.062
  BSA                                  0.46 (0.21--1.02)            0.057                              
  Active smoking                       0.88 (0.72--1.08)            0.229                              
  Diabetes                             1.91 (1.39--2.64)            0.001                              
  Hypertension                         1.94 (1.26--2.98)            0.002                              
  Dyslipidemia                         1.56 (1.06--2.30)            0.025                              
  Peripheral artery disease            2.36 (1.66--3.37)            0.001           1.88 (1.27--2.79)   0.002
  Previous stroke                      2.76 (1.89--4.02)            0.001           2.13 (1.41--3.22)   0.001
  Previous myocardial infarction       2.08 (1.49--2.89)            0.001                              
  Previous PCI                         1.34 (0.93--1.92)            0.119                              
  Previous malignancy                  1.66 (1.10--2.51)            0.016                              
  Previous bleeding                    1.79 (0.97--3.30)            0.064                              
  Charlson comorbidity Index           1.22 (1.12--1.32)            0.001                              
  Killip class on admission \>= II     2.69 (1.91--3.77)            0.001                              
  Heart rate                           1.02 (1.01--1.02)            0.001                              
  Creatinin clearance                  0.99 (0.98--0.99)            0.001                              
  Glucose at admission                 1.00 (1.00--1.01)            0.001                              
  LDL cholesterol                      0.99 (0.99--1.00)            0.041                              
  Left ventricle ejection fraction     0.97 (0.96--0.98)            0.001           0.99 (0.97--1.00)   0.082
  Multivessel disease                  1.39 (0.99--1.96)            0.058           1.24 (1.02--1.50)   0.028
  Left main disease                    2.01 (1.35--2.97)            0.001                              

BSA: body surface area; PCI: percutaneous coronary intervention.

![Cumulative incidence of mortality (A) and mortality or readmission at 6 months (B) according to anemia status.](jgc-17-01-035-g001){#jgc-17-01-035-g001}

4. Discussion {#s4}
=============

The main findings from this study are: (1) a significant proportion (31.3%) of these patients with NSTEACS had anemia at admission to ICCU; (2) patients with anemia had a significantly higher prevalence of comorbidities and higher risk criteria at admission; (3) despite the proportion was lower in patients with anemia, the vast majority of patients underwent coronary angiography during the admission (96.2%), and (4) patients with anemia had a higher incidence of mortality or readmission at 6 months, and this association was independent from potential confounders.

Anemia is a common comorbidity in ACS, and is strongly associated with poorer clinical outcomes in these patients[@b15]--[@b20] and also in other clinical settings.[@b21],[@b22] Prevalence of anemia in patients with ACS ranges between 20%--30% in most series, and is especially higher in elderly patients with comorbidities.[@b23]--[@b25] In contrast, other studies including highly selected ACS patients from clinical trials[@b26],[@b27] or assessing only patients treated with potent antiplatelet drugs[@b28] reported a significantly lower prevalence of anemia, around 10%. A not negligible proportion of patients with ACS and anemia are denied ICU admission in routine clinical practice because of a high degree of comorbidities and perception of a low life expectancy. Information about the real prevalence of anemia in high-risk ACS patients admitted to critical care units is scarce. In an interesting contribution, Uscinska, *et al*.[@b6] assessed a series of 392 patients admitted to an Intensive Cardiac Care Unit between 2008--2011 (mean age, 70 ± 13.8 year). Of them, 168 (42.9%) had diagnosis of ACS. The authors described a high prevalence of anemia according to WHO criteria in the whole cohort (64%), which was significantly lower in patients with ACS. Biomarkers of iron status but not anemia predicted in-hospital mortality. In another subanalysis of that series,[@b7] haemoglobin levels---along with age, parameters of iron status, and LVEF---were strong predictors of long-term mortality. Another small series[@b29] also described a high prevalence of anemia in ACS patients admitted to an ICCU. To our knowledge, no other study focused on ACS patients admitted to ICCU. Data from our study revealed that, despite being a relatively young population, almost one of each three of these high risk ACS patients admitted to ICCU had anemia at admission. This proportion is significantly lower than those observed in the series by Uscinska, *et al*.[@b6] Ours was a significantly younger homogeneous population in which we only assessed patients with NSTEACS diagnosis. On the other hand, different criteria for ICCU admission might also have contributed to the lower prevalence of anemia in our patients.

Patients with ACS and anemia are commonly managed conservatively in routine clinical practice,[@b4],[@b5],[@b23]--[@b25] with a lower likelihood of receiving potent antithrombotic drugs and undergoing coronary angiography or other intensive therapies. Therefore, little information exists about patients with high-risk ACS and anemia admitted to critical care units. In our opinion this is a crucial issue, since these patients are usually fully candidates to intensive therapies. Despite the performance of coronary angiography was less common in patients with anemia from our series, this invasive approach was selected in a high proportion of them (more than 90%). Interestingly, the performance of some ICCU procedures such as counterpulsation, non-invasive mechanical ventilation or renal replacement therapies were more common in this group, probably reflecting their higher profile of risk. In addition, a more conservative antithrombotic approach was used in patients with anemia, with a higher proportion of clopidogrel and lower of ticagrelor. Clopidogrel was the P2Y12 blocker more commonly used even in patients with normal haemoglobin values. This is also an interesting point, since recent data suggest that more antiplatelet drugs can be safely used in ACS patients with anemia with a careful assessment of ischemic and bleeding risk.[@b28]

Anemia was associated with a higher prevalence of comorbidities and severity of coronary disease in our patients. However, no significant differences were observed regarding the rate of revascularization according to anemia status. A potential reason for this might be the presence of more complex coronary lesions not suitable for revascularization in patients with anemia. The higher prevalence of comorbidities in patients with anemia might probably have contributed to the worse outcomes observed in these patients. However, after adjusting for potential confounders, anemia was independently associated to a higher incidence of events at follow up, as observed by Uscinska, *et al*.[@b7] In our opinion, these data support the need for a careful management and follow up in this group of complex ACS patients.

This study has some limitations, such as the moderate sample size of subgroups and the moderate number of events. It was an observational study, so we cannot rule out the presence of selection bias or residual confounding. In addition, data regarding type of anemia or iron status was not available. Finally, a longer follow up might have contributed to fully assess the association between anemia and outcomes.

Despite these limitations, in our opinion this study retrieves interesting and novel data about the real prevalence of anemia and its impact on management and prognosis of high-risk ACS patients admitted to ICCU in routine clinical practice. Improving risk stratification and outcomes in this growing group of complex patients often excluded form clinical trials might lead to important clinical and social consequences.

In conclusion, this study showed that almost one of each three patients with NSTEACS admitted to ICCU had anemia at admission. Patients with anemia had a significantly higher prevalence of comorbidities and higher risk criteria at admission, although they underwent less often coronary angiography. Anemia was independently associated to poorer outcomes in this group of high risk ACS patients undergoing a contemporary management at ICCU.

**Ethics statement:** All patients or their representatives signed an informed consent before being recruited for the study. Confidential information of the patients was protected according to national normative. This protocol has been approved by the Clinical Research Ethics Committee of Bellvitge University Hospital (IRB00005523).
